3rd Quarter - Report — ACADIA PHARMACEUTICALS for ACADIA PHARMACEUTICALS (2024)

Firm

ACADIA PHARMACEUTICALS

Client

ACADIA PHARMACEUTICALS

Income

—

Expenses

$220,000

Expense method

A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Implementation of the Inflation Reduction Act of 2022; Help Copays Act (HR 830 / S 1375); Orphan Cures Act (HR 5539 / S 3131); National Plan to End Parkinson's Act (HR 2365 / S 1064); Protect Rare Act (HR 6094); The Creating Hope Reauthorization Act (HR 7384 / S 4583) / HR 3433); BIOSECURE Act (HR 7085).

Lobbyist	Covered position, as disclosed
MICHAEL MATTOON	—

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 2365 (118th), H.R. 6094 (118th), H.R. 3433 (118th), H.R. 7085 (118th), H.R. 5539 (118th), H.R. 830 (118th), H.R. 7384 (118th)

Medicare/Medicaid MMM

Implementation of the Inflation Reduction Act of 2022; Issues related to protecting patient access to medicines in Medicare; Issues related to access to medicines for Parkinson's disease patients; Issues Related to Antipsychotic use in Medicaid (HR 4096); Orphan Cures Act (HR 5539 / S 3131); National Plan to End Parkinson's Act (HR 2365 / S 1064); Protect Rare Act (HR 6094); EPIC Act (HR 7174); BIOSECURE Act (HR 7085).

Lobbyist	Covered position, as disclosed
MICHAEL MATTOON	—

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 7174 (118th), H.R. 4096 (118th), H.R. 7085 (118th), H.R. 2365 (118th), H.R. 5539 (118th), H.R. 6094 (118th)

Trade (domestic/foreign) TRD

BIOSECURE Act (HR 7085).

Lobbyist	Covered position, as disclosed
MICHAEL MATTOON	—

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 7085 (118th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.